2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3194 Mechanisms of aberrant self-renewal in KAT6A-rearranged acute myeloid leukemia (AML)

Imaz Khalid, Joachim Wolff, PhD2, Kunzangla Bhutia3, Claudia Bruedigam, PhD4, Florian Perner, MD5, Wencke Walter, PhD6, Torsten Haferlach, MD, PhD7, Tina M. Schnoeder8, Florian H. Heidel IV, MD9
1 Hannover Medical School, Hannover, Niedersachsen, Germany
2 Hannover Medical School, Hannover, Niedersachsen, Germany
3 Hannover Medical School, Hannover, Niedersachsen, Germany
4 Monash University, Melbourne, Australia
5 Hannover Medical School, Hannover, Niedersachsen, Germany
6 MLL Munich Leukemia Laboratory, Munich, Germany
7 MLL Munich Leukemia Laboratory, Munich, Germany
8 Hannover Medical School, Hannover, Niedersachsen, Germany
9 Hannover Medical School, Hannover, Niedersachsen, Germany, Leibniz Institute on Aging, Jena, Germany

Reciprocal chromosomal rearrangements define biologically distinct subclasses of AML. The rare t(8;16)(p11;p13) translocation fuses KAT6A (MOZ) with CREBBP (CBP), accounts for 0.3% of AMLs and confers a poor prognosis. Distinctively among AML-fusions, it unites 2 histone acetyl-transferases from separate enzyme families (MYST, p300/CBP) within a single chimeric protein. The breakpoint characteristically retains the MYST-type catalytic HAT domain of KAT6A together with the bromodomain and HAT domains of CREBBP.

To define the genetic landscape of KAT6A::CREBBP (hereafter KC) AML, we analyzed the largest cohort to date (n=50): a complex karyotype (CK) was present in 31/50 patients (62%) and TP53 was the most frequent co-mutation (14/50; 28%), followed by TET2, ASXL1, and DNMT3A-frequencies far exceeding those in de novo and fusion driven AML (CK 10–12%; TP53 5–10%). This enrichment of KC and TP53/DTA co-mutations aligns KC-AML closely with secondary or adverse-risk AML.

To functionally assess for self-renewal capacity of KC-AMLs, we generated retroviral models for KC and 2 comparators: the related KAT6A::TIF2 (MT2) fusion and the canonical MLL::AF9 (MA9) (all in MSCV-IRES-GFP). In CFU-assays, KC-transduced murine HSPCs acquired serial replating capacity, albeit less robustly than MT2- or MA9-transformed cells. To assess disease propagation in vivo, equal numbers (5×104) of KC, MT2, or MA9 cells were transplanted into sublethally irradiated C57BL/6 mice. Here, KC recipients developed AML with comparable penetrance and latency (median OS: KC 29, MT2 29, MA9 26 days). KC-AML was characterized by leukocytosis, splenomegaly, and co-expression of monocytic markers. Consistently, a newly established KC-driven PDX-model showed stable engraftment in NXG recipients and serial transplantability with a median OS of 39 days.

Flow cytometric analysis of murine HSPC subsets was performed to define leukemia-initiating cells (LICs) in KC-AML. KC- and MA9-AMLs were dominated by granulocyte-macrophage progenitor (GMP)-like progenitors (Lin⁻Kit⁺Sca-1⁻CD34hiCD16/32hi; 61.6% and 95.6%, respectively). To assess for functional LICs in this compartment, we sorted GMP-like cells from KC-, MT2-, and MA9-AMLs and transplanted them at limiting dilution (5×105, 5×104, 5×103) into sublethally irradiated recipients. Here, KC-AML showed an LIC-frequency comparable to MA9 (1/33,099 vs 1/47,690).

To test whether KC-AML retains dependency on KAT6A catalytic activity, KAT6A was genetically and pharmacologically inactivated. The selective KAT6A/B inhibitor PF-9363 preferentially reduced KC-AML viability (at 500nM: 8.4%±3.2%) over MT2 (25.6%±8.0%) and MA9 (46.0%±15.9%). Mechanistically, PF-9363 suppressed H3K14 and H3K23 acetylation at nanomolar concentrations (50nM) in KC and MT2 but at micromolar doses (5µM) in MA9, indicating KAT6A-dependent maintenance of these marks in KAT6A-fusion leukemias.

Transcriptomic profiling of murine KC, MT2, and MA9 AMLs was performed to compare the transcriptional consequences of distinct epigenetically driven fusion-oncogenes. Although all 3 fusions converge on acetyltransferase/chromatin dysregulation, their transcriptomes appeared distinct. KC-AML was characterized by upregulation of stemness-associated genes (Mn1, Lin28b) and telomerase components (Terc, Tert). Consistently, the telomerase inhibitor imetelstat (IM) significantly reduced viability of KC-AML (at 5µM: 22.3% ± 3.06%), nominating IM as a therapeutic strategy for this poor-prognosis subtype, which responds poorly to conventional chemotherapy and hypomethylating agents.

As TP53 was the most frequent co-mutation in human KC-AML, we tested whether its loss may compromise these dependencies, generating CRISPR-engineered Trp53-knockout (p53-null) KC models. Both agents retained significant activity in the p53-null context and revealed suppressed proliferation (PF-9363, DMSO vs 500nM: p<0.0001; IM, DMSO vs 2.5µM: p<0.0001). Their combination resulted in synergistic activity (PF-9363/comb: p<0.0001; IM/comb: p<0.0552), an approach currently tested in PDX models.

Collectively, our integrated genetic and pharmacologic analysis defines t(8;16)/KC as a poor-prognosis, secondary AML-like disease marked by CK and TP53/DTA co-mutations. Despite uniting 2 histone acetyltransferases in one chimera, it remains dependent on KAT6A catalytic activity and a distinct stemness/telomerase transcriptional program, exposing KAT6A and telomerase inhibition as a rational therapeutic strategy.

Imaz Khalid: No relevant conflicts of interest to declare.